Ninevah Therapeutics is a discovery-stage company focused on bringing novel gene therapies to kidney patients.
There are more than 450 rare genetic kidney diseases for which there is no cure. In most cases, patients reach end-stage renal failure and require dialysis and a kidney transplant, which significantly affects their quality of life.
We are discovering gene therapies that have the potential to cure these patients.
Company Details
- Employees
- 1
- Founded
- 2019
- Address
- 10 John Street, London,england Wc1n 2eb,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ninevahtx.com
- Keywords
- kidney, gene therapy, orphan disease, gene editing.
- HQ
- London, England
Ninevah Therapeutics Questions
Ninevah Therapeutics's website is ninevahtx.com
Ninevah Therapeutics's LinkedIn profile is https://es.linkedin.com/company/ninevahtx
Ninevah Therapeutics has
1 employees.
View email and phone details for 1
employees at Ninevah Therapeutics.
Ninevah Therapeutics's industry is
Biotechnology Research
Ninevah Therapeutics's top competitors are
Akl Therapeutics,
Orthobio Therapeutics Inc.,
Alevin Therapeutics Ltd,
Kingdom Therapeutics Ltd,
Aptadel Therapeutics,
Orexia Therapeutics,
Added Health™,
Genetether Therapeutics Inc (Cse: Gttx),
Senolytic Therapeutics,
Talent Therapeutics.
Ninevah Therapeutics's categories are Biotechnology Research
Ninevah Therapeutics's founding year is 2019
